Cargando…
Integrated proteogenomic characterization of urothelial carcinoma of the bladder
BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-se...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164575/ https://www.ncbi.nlm.nih.gov/pubmed/35659036 http://dx.doi.org/10.1186/s13045-022-01291-7 |
_version_ | 1784720165460508672 |
---|---|
author | Xu, Ning Yao, Zhenmei Shang, Guoguo Ye, Dingwei Wang, Haixing Zhang, Hailiang Qu, Yuanyuan Xu, Fujiang Wang, Yunzhi Qin, Zhaoyu Zhu, Jiajun Zhang, Fan Feng, Jinwen Tian, Sha Liu, Yang Zhao, Jianyuan Hou, Jun Guo, Jianming Hou, Yingyong Ding, Chen |
author_facet | Xu, Ning Yao, Zhenmei Shang, Guoguo Ye, Dingwei Wang, Haixing Zhang, Hailiang Qu, Yuanyuan Xu, Fujiang Wang, Yunzhi Qin, Zhaoyu Zhu, Jiajun Zhang, Fan Feng, Jinwen Tian, Sha Liu, Yang Zhao, Jianyuan Hou, Jun Guo, Jianming Hou, Yingyong Ding, Chen |
author_sort | Xu, Ning |
collection | PubMed |
description | BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients (NMIBCs) and 71 muscle-invasive bladder cancer patients (MIBCs). RESULT: Proteogenomic integration analysis indicated that SND1 and CDK5 amplifications on chromosome 7q were associated with the activation of STAT3, which was relevant to tumor proliferation. Chromosome 5p gain in NMIBC patients was a high-risk factor, through modulating actin cytoskeleton implicating in tumor cells invasion. Phosphoproteomic analysis of tumors and morphologically normal human urothelium produced UC-associated activated kinases, including CDK1 and PRKDC. Proteomic analysis identified three groups, U-I, U-II, and U-III, reflecting distinct clinical prognosis and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested the amplification of TRAF2 related to the increased expression of PD-L1. Additionally, increased GARS, related to subtype U-II, was validated to promote pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. CONCLUSIONS: This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01291-7. |
format | Online Article Text |
id | pubmed-9164575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91645752022-06-04 Integrated proteogenomic characterization of urothelial carcinoma of the bladder Xu, Ning Yao, Zhenmei Shang, Guoguo Ye, Dingwei Wang, Haixing Zhang, Hailiang Qu, Yuanyuan Xu, Fujiang Wang, Yunzhi Qin, Zhaoyu Zhu, Jiajun Zhang, Fan Feng, Jinwen Tian, Sha Liu, Yang Zhao, Jianyuan Hou, Jun Guo, Jianming Hou, Yingyong Ding, Chen J Hematol Oncol Research BACKGROUND: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. METHODS: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients (NMIBCs) and 71 muscle-invasive bladder cancer patients (MIBCs). RESULT: Proteogenomic integration analysis indicated that SND1 and CDK5 amplifications on chromosome 7q were associated with the activation of STAT3, which was relevant to tumor proliferation. Chromosome 5p gain in NMIBC patients was a high-risk factor, through modulating actin cytoskeleton implicating in tumor cells invasion. Phosphoproteomic analysis of tumors and morphologically normal human urothelium produced UC-associated activated kinases, including CDK1 and PRKDC. Proteomic analysis identified three groups, U-I, U-II, and U-III, reflecting distinct clinical prognosis and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested the amplification of TRAF2 related to the increased expression of PD-L1. Additionally, increased GARS, related to subtype U-II, was validated to promote pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. CONCLUSIONS: This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-022-01291-7. BioMed Central 2022-06-03 /pmc/articles/PMC9164575/ /pubmed/35659036 http://dx.doi.org/10.1186/s13045-022-01291-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Xu, Ning Yao, Zhenmei Shang, Guoguo Ye, Dingwei Wang, Haixing Zhang, Hailiang Qu, Yuanyuan Xu, Fujiang Wang, Yunzhi Qin, Zhaoyu Zhu, Jiajun Zhang, Fan Feng, Jinwen Tian, Sha Liu, Yang Zhao, Jianyuan Hou, Jun Guo, Jianming Hou, Yingyong Ding, Chen Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title | Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title_full | Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title_fullStr | Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title_full_unstemmed | Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title_short | Integrated proteogenomic characterization of urothelial carcinoma of the bladder |
title_sort | integrated proteogenomic characterization of urothelial carcinoma of the bladder |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164575/ https://www.ncbi.nlm.nih.gov/pubmed/35659036 http://dx.doi.org/10.1186/s13045-022-01291-7 |
work_keys_str_mv | AT xuning integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT yaozhenmei integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT shangguoguo integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT yedingwei integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT wanghaixing integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT zhanghailiang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT quyuanyuan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT xufujiang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT wangyunzhi integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT qinzhaoyu integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT zhujiajun integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT zhangfan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT fengjinwen integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT tiansha integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT liuyang integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT zhaojianyuan integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT houjun integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT guojianming integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT houyingyong integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder AT dingchen integratedproteogenomiccharacterizationofurothelialcarcinomaofthebladder |